Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOD1 | P00441 | 11/20 | 1.00 |
| ▸ | MAOB | P27338 | 6/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | DAO | P14920 | 2/20 | 0.50 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12297919 | 0.83 | SOD1 (1.00) | SOD1CYP2C19DAOPARP15PARP10 | |
| SCHEMBL19559177 | 0.82 | SOD1 (0.77) | SOD1CYP2C19DAO | |
| SCHEMBL12297769 | 0.80 | SOD1 (1.00) | SOD1CYP2C19DAO | |
| SCHEMBL12297884 | 0.79 | SOD1 (1.00) | SOD1CYP2C19DAO | |
| SCHEMBL12297886 | 0.78 | SOD1 (1.00) | SOD1CYP2C19DAO | |
| SCHEMBL12297901 | 0.73 | SOD1 (0.71) | SOD1MAOBCYP2C19DAO | |
| SCHEMBL12297784 | 0.73 | SOD1 (0.71) | SOD1CYP2C19DAO | |
| SCHEMBL12297382 | 0.72 | SOD1 (1.00) | SOD1CYP2C19DAO | |
| SCHEMBL12297771 | 0.72 | SOD1 (1.00) | SOD1CYP2C19DAO | |
| SCHEMBL4404036 | 0.71 | MAOB (1.00) | MAOBPARP15PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167263-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2019-01-01 | — | — | US | disclosed |
| EP-2367798-B1 | PYRAZOLONE DERIVATIVES USEFUL IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV NORTHWESTERN (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170349552-A1 | Treatment of Amyotrophic Lateral Sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-12-07 | — | — | US | disclosed |
| US-9809556-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160016911-A1 | Treatment of Amyotrophic Lateral Sclerosis | NORTHWESTERN UNIVERSITY | 2016-01-21 | — | — | US | disclosed |
| US-20160016911-A1 | Treatment of Amyotrophic Lateral Sclerosis | NORTHWESTERN UNIVERSITY | 2016-01-21 | — | — | US | disclosed |
| US-9145424-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145424-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2015-09-29 | — | — | US | disclosed |
| US-20110237907-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237907-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2010059241-A2 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016911-A1 | Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, SOD1, NLN | SOD1 2/4885MAOB 648/4885CYP2C19 4689/4885 |
| US-10167263-B2 | Treatment of amyotrophic lateral sclerosis | SMN1; SMN2, SOD1, NLN | SOD1 2/4885MAOB 648/4885CYP2C19 4689/4885 |
| US-20170349552-A1 | Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, SOD1, NLN | SOD1 2/4885MAOB 648/4885CYP2C19 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.